Heat Biologics to Present at LHA Life Sciences & Medical Technologies Virtual Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Feb 15, 2012-- Heat Biologics, Inc. (the "Company" or "Heat"), a clinical-stage immunotherapy company, today announced that Jeffrey Wolf, Chief Executive Officer of Heat Biologics, will present to investors as part of the LHA Life Sciences & Medical Technologies Virtual Conference on Thursday, February 16, 2012, at 10:00 a.m. Eastern time.
The webcast of the Heat Biologics' presentation will be accessible live and for 30 days at www.heatbio.com or at the PrecisionIR event site at http://www.investorcalendar.com/IC/CEPage.asp?ID167401.
This virtual conference event includes 30-minute presentations with accompanying slides from eight industry leaders, and begins at 9:00 a.m. Eastern time.
About Heat Biologics, Inc.
Heat Biologics (www.heatbio.com) ("Heat") is a clinical-stage company immunotherapy company focused on developing its novel off-the-shelf "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy) therapeutic vaccines to combat a wide range of cancers and other diseases. Heat's ImPACT Therapy effectively reprograms tumor cells to "pump out" an important immuno-protein called "gp96-Ig" and their chaperoned antigens to robustly stimulate the immune system against the targeted disease.
Heat's ImPACT Therapy is based upon heat shock protein gp-96, a chaperone protein found in all huma cells and normally tethered to our cells with a leash called the KDEL sequence. ImPACT Therapy removes this KDEL leash, thus transforming allogeneic living cells into powerful machines that continually pump out gp96 and their chaperoned antigens to activate the immune system against the full spectrum of antigens expressed by a patient's disease. Heat is currently in Phase IIa trials against non-small cell lung cancer. Positive prophylactic and therapeutic data against SIV (the primate equivalent of HIV) has also been generated in a large 48-primate NIH-sponsored study, the first of ImPACT's ability to combat viral diseases. Heat plans to initiate additional clinical trials against bladder and ovarian cancer in 2012.
CONTACT: Heat Biologics, Inc.
Jeffrey Wolf, 919-240-7133 Chief Executive Officer or Investor Inquiries LHA Anne Marie Fields, 212-838-3777 email@example.com or Bruce Voss, 310-691-7100 firstname.lastname@example.org @LHA_IR_PR KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL SOURCE: Heat Biologics, Inc.
Copyright Business Wire 2012 PUB: 02/15/2012 10:23 AM/DISC: 02/15/2012 10:23 AM http://www.businesswire.com/news/home/20120215006070/